查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1581227

核酸藥物市場：按核酸類型、藥物傳輸、治療應用和最終用戶分類 - 2025-2030 年全球預測

Nucleic Acid-Based Drugs Market by Nucleic Acid Type (DNA-based Drugs, RNA-based Drugs), Drug Type (Long-Chain Nucleic Acid Drugs, Short-Chain Nucleic Acid Drugs), Method of Delivery, Therapeutic Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年核酸藥物市值為47.6億美元，預計到2024年將達到54.6億美元，複合年成長率為15.09%，到2030年將達到127.4億美元。

核酸藥物是源自天然或合成核酸（例如DNA、RNA、適體和寡核苷酸）的治療劑，用於透過靶向特定的分子機制來治療各種遺傳性感染疾病。這種需求源自於其直接改變基因表現的能力，提供高度標靶化的治療，與傳統藥物相比，副作用可能較少。這些藥物在基因治療、反義治療和RNA干擾等領域有應用，有助於癌症、心血管和感染疾病治療等最終用途領域。基因研究的進步、藥物輸送系統的技術創新以及個人化醫療投資的增加推動了核酸藥物市場的發展。關鍵的成長要素包括遺傳性疾病盛行率的上升、開發針對 COVID-19 等病毒感染疾病的治療方法的迫切性，以及強大的標靶治療標記產品線。新的商機正在將應用擴展到腫瘤學之外，包括在神經退化性疾病疾病和代謝疾病方面的巨大潛力。為了利用這些機會，公司應該投資加強藥物輸送機制，以提高核酸藥物的穩定性和吸收率，並在藥物開發過程中利用人工智慧。然而，高昂的開發成本、複雜的法律規範、向目標細胞遞送的挑戰以及潛在的脫靶效應等限制構成了主要障礙。智慧財產權的排他性和產品的特殊性也限制了市場的擴張。非病毒傳遞方法的創新，例如奈米顆粒和綴合技術，是有前景的研究和業務成長領域。生物技術公司和研究機構之間的合作也可能帶來突破，解決當前的交付和穩定性挑戰。該市場的特點是快速發展，強調了敏捷反應和持續投資研發以推進核酸療法並充分發揮其治療潛力的重要性。

主要市場統計
基準年[2023] 47.6億美元
預測年份 [2024] 54.6億美元
預測年份 [2030] 127.4億美元
複合年成長率（%） 15.09%

市場動態：揭示快速發展的核酸藥物市場的關鍵市場洞察

核酸藥物市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球慢性病流行
    • 對個人化醫療的認知和接受度不斷提高
  • 市場限制因素
    • 基於核酸的療法成本高昂
  • 市場機會
    • 擴大核酸藥物在罕見遺傳疾病治療的應用
    • 製藥和生技公司之間的合作不斷加強
  • 市場挑戰
    • 確保核酸藥物穩定性和傳遞的局限性

波特五力：駕馭核酸藥物市場的策略工具

波特的五力架構是了解核酸藥物市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解核酸藥物市場的外部影響

外部宏觀環境因素對核酸藥物市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解核酸藥物市場競爭態勢

對核酸藥物市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣核酸藥物市場供應商績效評估

FPNV定位矩陣是評估核酸藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了核酸藥物市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對核酸藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地慢性病的盛行率不斷上升
      • 對個人化醫療的認知和接受度不斷提高
    • 抑制因素
      • 基於核酸的療法高成本
    • 機會
      • 擴大核酸藥物在罕見遺傳疾病治療的應用
      • 製藥和生物技術公司之間合作的演變
    • 任務
      • 確保核酸藥物穩定性和傳遞的局限性
  • 市場區隔分析
    • 核酸類型：標靶遺傳物質的特異性和效率為基於 RNA 的藥物帶來了新的應用。
    • 治療應用：核酸藥物在神經系統疾病的多樣化應用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 核酸藥物市場（依核酸類型分類）

  • 基於DNA的醫學
  • 基於RNA的醫學

第7章 核酸藥物市場（依藥物類型）

  • 長鏈核酸藥物
  • 短鏈核酸藥物

第8章以遞送方式分類的核酸藥物市場

  • 在地化交付
  • 全身給藥

第9章基於治療應用的核酸藥物市場

  • 心血管疾病
  • 感染疾病
  • 神經系統疾病
  • 腫瘤學
  • 罕見疾病和遺傳疾病

第10章基於核酸的藥物市場：依最終用戶分類

  • 生物製藥公司
  • 醫院/診所
  • 調查機構

第11章 美洲核酸藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章 亞太地區核酸藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章 歐洲、中東和非洲核酸藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • GlaxoSmithKline Plc)以 5,000 萬美元收購 Elsie Biotechnologies，作為加速核酸藥物開發策略舉措的一部分。
    • 沃特世公司推出先進的 SEC管柱來加速基因為基礎的藥物開發。
    • 旭化成生物製程公司 (Asahi Kasei Bioprocess) 與 Axolabs GmbH 合作加速創新基因療法的開發
  • 戰略分析和建議

公司名單

  • Alnylam Pharmaceuticals, Inc.
  • Arcturus Therapeutics Holdings Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Beam Therapeutics Inc.
  • BioMarin Pharmaceutical Inc.
  • Bluebird Bio, Inc.
  • CRISPR Therapeutics AG
  • CureVac NV
  • Dicerna Pharmaceuticals, Inc.
  • Dynavax Technologies Corporation
  • Editas Medicine, Inc.
  • Evotec SE
  • Generation Bio Co.
  • Ionis Pharmaceuticals, Inc.
  • Moderna, Inc.
  • ProQR Therapeutics NV
  • Sangamo Therapeutics, Inc
  • Sarepta Therapeutics, Inc.
  • Senti Biosciences, Inc.
  • Silence Therapeutics Plc
  • Stoke Therapeutics, Inc.
  • Translate Bio, Inc. by Sanofi SA
  • Voyager Therapeutics, Inc.
  • Wave Life Sciences Ltd.
Product Code: MRR-CA7E340319CE

The Nucleic Acid-Based Drugs Market was valued at USD 4.76 billion in 2023, expected to reach USD 5.46 billion in 2024, and is projected to grow at a CAGR of 15.09%, to USD 12.74 billion by 2030.

Nucleic acid-based drugs are therapeutic agents derived from natural or synthetic nucleic acids, such as DNA, RNA, aptamers, and oligonucleotides, aimed at treating a variety of genetic and infectious diseases by targeting specific molecular mechanisms. Their necessity arises from their ability to directly alter genetic expression, offering highly targeted treatments with potentially fewer side effects compared to traditional drugs. These drugs are applied in areas like gene therapy, antisense therapy, and RNA interference, serving end-use sectors including oncology, cardiovascular, and infectious disease treatment, among others. The market for nucleic acid-based drugs is being fueled by advances in genetic research, technological innovations in drug delivery systems, and increasing investment in personalized medicine. Key growth factors include rising prevalence of genetic disorders, urgency in developing treatments for viral infections like COVID-19, and robust pipelines of biomarkers for targeted therapies. Emerging opportunities lie in expanding applications beyond oncology, with significant potential in neurodegenerative and metabolic disorders. To capitalize on these opportunities, companies should invest in enhancing delivery mechanisms to improve the stability and uptake of nucleic acid drugs and leverage artificial intelligence in drug development processes. However, limitations such as high development costs, complex regulatory frameworks, challenges in delivery to target cells, and potential off-target effects pose significant hurdles. The exclusivity of intellectual property and product specificity also restrict market expansion. Innovations in non-viral delivery methods, like nanoparticles and conjugation technologies, represent promising areas for research and business growth. Collaborations between biotech firms and research institutions can also spark breakthroughs in solving current delivery and stability challenges. The market is characterized by rapid developments, emphasizing the importance of agility and sustained investment in R&D to drive forward nucleic acid-based therapies and fully exploit their therapeutic potential.

KEY MARKET STATISTICS
Base Year [2023] USD 4.76 billion
Estimated Year [2024] USD 5.46 billion
Forecast Year [2030] USD 12.74 billion
CAGR (%) 15.09%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Nucleic Acid-Based Drugs Market

The Nucleic Acid-Based Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of chronic diseases across the globe
    • Rising awareness and acceptance of personalized medicine
  • Market Restraints
    • High costs of nucleic acid-based therapies
  • Market Opportunities
    • Expanding applications of nucleic acid-based drugs in treating rare genetic disorders
    • Evolving collaboration between pharmaceutical companies and biotechnology firms
  • Market Challenges
    • Limitations in ensuring the stability and delivery of nucleic acid-based drugs

Porter's Five Forces: A Strategic Tool for Navigating the Nucleic Acid-Based Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Nucleic Acid-Based Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Nucleic Acid-Based Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Nucleic Acid-Based Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Nucleic Acid-Based Drugs Market

A detailed market share analysis in the Nucleic Acid-Based Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Nucleic Acid-Based Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Nucleic Acid-Based Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Nucleic Acid-Based Drugs Market

A strategic analysis of the Nucleic Acid-Based Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Nucleic Acid-Based Drugs Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals, Inc., Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals, Inc., Beam Therapeutics Inc., BioMarin Pharmaceutical Inc., Bluebird Bio, Inc., CRISPR Therapeutics AG, CureVac N.V., Dicerna Pharmaceuticals, Inc., Dynavax Technologies Corporation, Editas Medicine, Inc., Evotec SE, Generation Bio Co., Ionis Pharmaceuticals, Inc., Moderna, Inc., ProQR Therapeutics N.V., Sangamo Therapeutics, Inc, Sarepta Therapeutics, Inc., Senti Biosciences, Inc., Silence Therapeutics Plc, Stoke Therapeutics, Inc., Translate Bio, Inc. by Sanofi SA, Voyager Therapeutics, Inc., and Wave Life Sciences Ltd..

Market Segmentation & Coverage

This research report categorizes the Nucleic Acid-Based Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Nucleic Acid Type, market is studied across DNA-based Drugs and RNA-based Drugs.
  • Based on Drug Type, market is studied across Long-Chain Nucleic Acid Drugs and Short-Chain Nucleic Acid Drugs.
  • Based on Method of Delivery, market is studied across Localized Delivery and Systemic Delivery.
  • Based on Therapeutic Application, market is studied across Cardiovascular Diseases, Infectious Diseases, Neurological Disorders, Oncology, and Rare & Genetic Disorders.
  • Based on End-User, market is studied across Biopharmaceutical Companies, Hospitals & Clinics, and Research Organizations.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of chronic diseases across the globe
      • 5.1.1.2. Rising awareness and acceptance of personalized medicine
    • 5.1.2. Restraints
      • 5.1.2.1. High costs of nucleic acid-based therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Expanding applications of nucleic acid-based drugs in treating rare genetic disorders
      • 5.1.3.2. Evolving collaboration between pharmaceutical companies and biotechnology firms
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations in ensuring the stability and delivery of nucleic acid-based drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Nucleic Acid Type: Emerging application of RNA-based drugs owing to specificity and efficiency in targeting genetic material
    • 5.2.2. Therapeutic Application: Diverse applications of nucleic acid-based drugs in neurological disorders
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Nucleic Acid-Based Drugs Market, by Nucleic Acid Type

  • 6.1. Introduction
  • 6.2. DNA-based Drugs
  • 6.3. RNA-based Drugs

7. Nucleic Acid-Based Drugs Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Long-Chain Nucleic Acid Drugs
  • 7.3. Short-Chain Nucleic Acid Drugs

8. Nucleic Acid-Based Drugs Market, by Method of Delivery

  • 8.1. Introduction
  • 8.2. Localized Delivery
  • 8.3. Systemic Delivery

9. Nucleic Acid-Based Drugs Market, by Therapeutic Application

  • 9.1. Introduction
  • 9.2. Cardiovascular Diseases
  • 9.3. Infectious Diseases
  • 9.4. Neurological Disorders
  • 9.5. Oncology
  • 9.6. Rare & Genetic Disorders

10. Nucleic Acid-Based Drugs Market, by End-User

  • 10.1. Introduction
  • 10.2. Biopharmaceutical Companies
  • 10.3. Hospitals & Clinics
  • 10.4. Research Organizations

11. Americas Nucleic Acid-Based Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Nucleic Acid-Based Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Nucleic Acid-Based Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. GlaxoSmithKline PLC acquired Elsie Biotechnologies, LLC for USD 50 Million in a strategic move to boost nucleic acid drug development
    • 14.3.2. Waters Corporation introduced advanced SEC columns to accelerate gene-based drug development
    • 14.3.3. Asahi Kasei Bioprocess and Axolabs GmbH partner to accelerate the development of innovative gene-based therapies
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alnylam Pharmaceuticals, Inc.
  • 2. Arcturus Therapeutics Holdings Inc.
  • 3. Arrowhead Pharmaceuticals, Inc.
  • 4. Beam Therapeutics Inc.
  • 5. BioMarin Pharmaceutical Inc.
  • 6. Bluebird Bio, Inc.
  • 7. CRISPR Therapeutics AG
  • 8. CureVac N.V.
  • 9. Dicerna Pharmaceuticals, Inc.
  • 10. Dynavax Technologies Corporation
  • 11. Editas Medicine, Inc.
  • 12. Evotec SE
  • 13. Generation Bio Co.
  • 14. Ionis Pharmaceuticals, Inc.
  • 15. Moderna, Inc.
  • 16. ProQR Therapeutics N.V.
  • 17. Sangamo Therapeutics, Inc
  • 18. Sarepta Therapeutics, Inc.
  • 19. Senti Biosciences, Inc.
  • 20. Silence Therapeutics Plc
  • 21. Stoke Therapeutics, Inc.
  • 22. Translate Bio, Inc. by Sanofi SA
  • 23. Voyager Therapeutics, Inc.
  • 24. Wave Life Sciences Ltd.

LIST OF FIGURES

  • FIGURE 1. NUCLEIC ACID-BASED DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. NUCLEIC ACID-BASED DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. NUCLEIC ACID-BASED DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NUCLEIC ACID-BASED DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NUCLEIC ACID-BASED DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DNA-BASED DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA-BASED DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY LONG-CHAIN NUCLEIC ACID DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT-CHAIN NUCLEIC ACID DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY LOCALIZED DELIVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SYSTEMIC DELIVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RARE & GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 235. NUCLEIC ACID-BASED DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 236. NUCLEIC ACID-BASED DRUGS MARKET, FPNV POSITIONING MATRIX, 2023